The safety label for the medical contrast agent Optiray (ioversol) is being updated under the Warnings and Precautions section to include the risk of severe cutaneous adverse reactions (SCAR), which may develop from one hour to several weeks after intravascular contrast agent administration, the Food and Drug Administration (FDA) announced. “These reactions include Stevens-Johnson Syndrome and toxic epidermial necrolysis (SJS/TENS), acute generalized Exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS). Reaction severity may increase and time to onset may decrease with repeat administration of contrast agent,” the updated label states. Optiray is a radiopaque contrast agent ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.